Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;10(4):1410-1417.
doi: 10.21037/gs-21-157.

Mutational landscape of thymic epithelial tumors in a Chinese population: insights into potential clinical implications

Hongbiao Wang  1 , Xiaohua Xu  2 , Lan Luo  3 , Chunbing Wang  4 , Zeyong Jiang  5 , Yingcheng Lin  1
Affiliations

Mutational landscape of thymic epithelial tumors in a Chinese population: insights into potential clinical implications

Hongbiao Wang et al. Gland Surg. 2021 Apr.

Abstract

Background: Thymic epithelial tumors (TETs) are a heterogeneous group of rare malignancies which may be devastating, difficult to treat, and for which treatment options are limited. Herein, we investigated the comprehensive genomic alterations of TETs in a Chinese population for providing clinical management, especially targeted therapy.

Methods: Comprehensive genomic profiling (CGP) was performed with DNA targeted sequencing of cancer-associated genes (CSYS) from a cohort of 40 Chinese TET patients. TMB was measured by an in-house algorithm. MSI status was inferred based on the MANTIS (Microsatellite Analysis for Normal-Tumor InStability) score. The expression status of PD-L1 was estimated by immunohistochemistry.

Results: The mutational profiling of thymomas (Ts) and thymic neuroendocrine tumors (TNETs) showed scattered mutation distributions with no recurrently mutated genes. In contrast, thymic carcinomas (TCs) did show highly recurrent mutations including CDKN2A, CYLD, CDKN2B, and TP53. Among them, CDKN2A and CDKN2B mutations were the top potentially actionable alterations in TCs. PD-L1 expression was mainly present in Ts and TCs, and was predominant in males and smokers.

Conclusions: Our study provided a comprehensive genetic alteration view on the largest Chinese cohort of TETs to date. The results identified different genomic mutational profiles of Ts, TCs, and TNETs, and analyzed potential druggable biomarkers with clinical implications in Chinese TET patients, which provided the evidence for precision medicine of rare TET patients.

Keywords: Thymic epithelial tumors (TETs); actionable mutations; mutational landscape; thymic carcinomas (TCs); thymic neuroendocrine tumors (TNETs); thymomas (Ts).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/gs-21-157). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Molecular landscape of genetic alterations in all 40 TETs. TET, thymic epithelial tumor; T, thymoma; TC, thymic carcinoma; TNET, thymic neuroendocrine tumor.
Figure 2
Figure 2
Actionable mutations identified in 40 TETs. TET, thymic epithelial tumor.
See this image and copyright information in PMC

References

    1. Marx A, Chan JK, Coindre JM, et al. The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes. J Thorac Oncol 2015;10:1383-95. 10.1097/JTO.0000000000000654 - DOI - PMC - PubMed
    1. Travis WD, Brambilla E, Burke AP, et al. WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart. Forth edition. WHO Classification of Tumors. Volume 7. Vol. 7: World Health Organization. 2015. - PubMed
    1. Fang W, Fu J, Shen Y, et al. Management of thymic tumors-consensus based on the Chinese Alliance for Research in Thymomas Multi-institutional retrospective studies. J Thorac Dis 2016;8:641-5. 10.21037/jtd.2016.03.23 - DOI - PMC - PubMed
    1. Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol 2010;5:S260-5. 10.1097/JTO.0b013e3181f1f62d - DOI - PMC - PubMed
    1. Marx A. SP, Zettl A., et al. Thymomas. In: Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC (eds). World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, thymus and heart, vol. 7. Lyon, IARC Press. 2004:152-3.